X4 Pharmaceuticals, Inc.
XFOR
$3.58
$0.082.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 37.23% | -7,277.66% | 39.92% | 18.75% | -128.34% |
| Total Depreciation and Amortization | 180.85% | -53.15% | -18.32% | -16.48% | 82.99% |
| Total Amortization of Deferred Charges | 12.74% | 2.22% | 2.99% | 13.92% | 2.42% |
| Total Other Non-Cash Items | 654.91% | 125.83% | -52.48% | -44.20% | 99.58% |
| Change in Net Operating Assets | -107.87% | 26.46% | 361.37% | 63.47% | -501.53% |
| Cash from Operations | 30.48% | -58.47% | 52.94% | 18.25% | 1.24% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -104.33% | 713.51% | 296.38% | -81.03% | 388.76% |
| Cash from Investing | -104.33% | 713.51% | 295.44% | -79.98% | -76.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.67% | -- | 108,116.30% | -- | 3,441.51% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -98.67% | -- | 108,116.30% | -- | -72.07% |
| Foreign Exchange rate Adjustments | -103.60% | -127.78% | 101.23% | -100.61% | 872.22% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,031.31% | 97.64% | 453.31% | 161.08% | -101.17% |